Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Gain Therapeutics logo — Unfolding the next generation of allosteric small molecule t...

Gain Therapeutics

Unfolding the next generation of allosteric small molecule therapies to meet patient needs

Founded 2017 United States Bethesda, United States 26 employees IPO Total: $83.04M Biotechnology, Pharmaceutical

General Information

Company Name Gain Therapeutics
Founded Year 2017
Location United States Bethesda, United States
Employees 26
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Business Model B2B, Platform
Revenue Model Licensing, Product Sales, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with Gain Therapeutics. To contact Gain Therapeutics, visit gaintherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Gain Therapeutics compare?

A PDF of Gain Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Gain Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Gain Therapeutics

Gain Therapeutics, founded in 2017, is a clinical-stage biotechnology company spearheading the development of next-generation allosteric therapies. Its lead drug candidate, GT-02287, is under evaluation for Parkinson’s disease, targeting patients with or without a GBA1 mutation. Phase 1 results in healthy volunteers have shown promising safety profiles, therapeutic-range plasma exposure, and effective CNS engagement.

Deploying its state-of-the-art Magellan™ platform, Gain Therapeutics is pioneering efforts in discovering novel, allosteric small-molecule modulators to influence protein function. This innovation is poised to unlock therapies for previously intractable diseases, including neurodegenerative disorders, rare genetic disorders, and oncology.

The company recently secured a $7.00M Post IPO Equity investment on 01 July 2025, reflecting strong confidence from investors in its strategic approach to transformative drug discovery.

Business keywords: clinical-stage, allosteric therapies, drug discovery, GT-02287, Parkinson's disease, GBA1 mutation, Magellan platform, neurodegenerative diseases, rare genetic disorders, oncology, lysosomal storage disorders, pharmacological chaperones, protein modulation, disease-modifying treatments

Services & Products

Drug Discovery and Development
Clinical Research
AI-driven Therapeutics
Protein Modulation Technologies

Target Customers

Pharmaceutical Companies Research Institutions Healthcare Providers Patients with Neurodegenerative Diseases

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $7.00M -
01 Jul 2025
Post-IPO Equity $11.00M -
01 Jun 2024
Post-IPO Equity $9.40M -
01 Nov 2023
Grant $2.80M 1
Innosuisse
Innosuisse
01 May 2023
IPO $40.00M -
01 Mar 2021
Series B $10.00M -
01 Jul 2020
Grant Undisclosed -
01 Oct 2019
Series A $2.84M 2
3B Future Health Fund TiVentures
3B Future Health Fund, TiVentures
01 Feb 2019
Corporate Spinout Undisclosed 1
Minoryx Therapeutics
01 Jul 2017

Gain Therapeutics Alternatives & Competitors

View All Alternatives
Gain Therapeutics vs
Addex Therapeutics
Addex Therapeutics Switzerland

Allosteric modulators for Human Health

Post-IPO Equity
19 employees
Biotechnology, Health Care
Compare Gain Therapeutics vs Addex Therapeutics
Gain Therapeutics vs
Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. United States

Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.

Grant
13 employees
Biotechnology, Pharmaceutical
Gain Therapeutics vs
Wren Therapeutics
Wren Therapeutics United Kingdom

Stopping the wave of neurodegeneration at its source

Venture round
34 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Gain Therapeutics

Unfolding the next generation of allosteric small molecule therapies to meet patient needs
Gain Therapeutics was founded in 2017.
Gain Therapeutics is headquartered in Bethesda, United States.
Gain Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on clinical-stage, allosteric therapies, drug discovery and GT-02287. Its customers include Pharmaceutical Companies, Research Institutions and Healthcare Providers.
Gain Therapeutics has a B2B and Platform business model. Its revenue comes from Licensing, Product Sales and Value Based Pricing.
Gain Therapeutics has approximately 26 employees.
Gain Therapeutics has completed 9 funding rounds, raising a total of $83.04M. The latest funding stage is IPO.
Gain Therapeutics offers: Drug Discovery and Development, Clinical Research, AI-driven Therapeutics, Protein Modulation Technologies.
Top alternatives and competitors to Gain Therapeutics include Addex Therapeutics, Cantabio Pharmaceuticals, Inc., Wren Therapeutics, Alector, KeifeRx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gain Therapeutics and Addex Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Gain Therapeutics, https://bouncewatch.com/company/gain-therapeutics, updated 28 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout